MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2026.1821495

Медицинская библиотека · Frontiers in immunology · 2026

Development of a GMMA-based candidate vaccine against invasive nontyphoidal Salmonella disease.

Citiulo Francesco, Koeberling Oliver, Rossi Omar, Cappelletti Emilia, Giannelli Carlo, Aruta Maria Grazia, De Simone Daniele, Pippi Federico, Ferhati Xhenti, De Felice Antonia, Acquaviva Alessandra, Daniele Angela, De Luca Filomena, Iannello Giulia, Vitali Claudia G, Necchi Francesca, Martin Laura B, Berlanda Scorza Francesco, Colucci Anna Maria, Canals Rocío

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Invasive nontyphoidal Salmonella (iNTS) disease is one of the most common causes of bacteremia in sub-Saharan Africa (sSA), mostly affecting children less than 5 years of age and with an associated 14.7% case fatality ratio. This disease is responsible for 62,018 deaths worldwide annually with more than 80% of those occurring in sSA.

METHODS

This work describes the pre-clinical development of a Generalized Modules for Membrane Antigens (GMMA)-based bivalent vaccine candidate against iNTS disease, known as iNTS-GMMA. Salmonella enterica serovars Typhimurium (S. Typhimurium) and Enteritidis (S. Enteritidis) were genetically modified to induce hyperblebbing of outer membrane vesicles, referred to as GMMA, with a penta-acylated lipid A of the lipopolysaccharide (LPS), characterized by a reduced induction of proinflammatory cytokine release from monocytes compared to GMMA carrying wild-type species of lipid A. GMMA derived from the genetically modified Salmonella strains were produced at scale with high yields and purity under both non-good manufacturing practice (GMP) conditions and under GMP conditions. A simple two-step filtration process was used to purify the GMMA drug substances. Subsequently, the S. Typhimurium GMMA and S. Enteritidis GMMA were individually formulated on Alhydrogel to produce the drug products. Mixing of the two components prior to injection results in the iNTS-GMMA vaccine candidate.

RESULTS

The iNTS-GMMA vaccine candidate induced in mice and rabbits high levels of IgG anti-S. Typhimurium and S. Enteritidis LPS O-antigens, the target antigens of the vaccine. Moreover, animal sera elicited strong in vitro bactericidal activity against S. Typhimurium and S. Enteritidis strains. Additionally, the highest envisioned human dose of iNTS-GMMA was well tolerated in a GLP repeated-dose toxicology study in rabbits.

CONCLUSIONS

These data supported clinical evaluation of this urgently needed vaccine against iNTS disease in sSA.

Для цитирования: Citiulo Francesco, Koeberling Oliver, Rossi Omar, Cappelletti Emilia, Giannelli Carlo, Aruta Maria Grazia, De Simone Daniele, Pippi Federico, Ferhati Xhenti, De Felice Antonia, Acquaviva Alessandra, Daniele Angela, De Luca Filomena, Iannello Giulia, Vitali Claudia G, Necchi Francesca, Martin Laura B, Berlanda Scorza Francesco, Colucci Anna Maria, Canals Rocío. Development of a GMMA-based candidate vaccine against invasive nontyphoidal Salmonella disease.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1821495.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.